Javier Machín Gayarre

Table S1 from Pathological Response in a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined Classification

Isabel Echavarría, Sara López‐Tarruella, Antoni C. Picornell, José Á. García-Sáenz et autres

Table S1 Response among mutation carriers among mutation carriers (number of patients.)

Table S1 from Pathological Response in a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined Classification

Isabel Echavarría, Sara López‐Tarruella, Antoni C. Picornell, José Á. García-Sáenz et autres

Table S1 Response among mutation carriers among mutation carriers (number of patients.)

Data from Pathological Response in a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined Classification

Isabel Echavarría, Sara López‐Tarruella, Antoni C. Picornell, José Á. García-Sáenz et autres

Abstract Purpose: Triple-negative breast cancer (TNBC) requires the iden- tification of reliable predictors of response to neoadjuvant chemotherapy (NACT). For this purpose, we aimed to evaluate the performance of the TNBCtype-4 classifier in a cohort of patients with TNBC treated with neoadjuvant …

Data from Pathological Response in a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined Classification

Isabel Echavarría, Sara López‐Tarruella, Antoni C. Picornell, José Á. García-Sáenz et autres

Abstract Purpose: Triple-negative breast cancer (TNBC) requires the iden- tification of reliable predictors of response to neoadjuvant chemotherapy (NACT). For this purpose, we aimed to evaluate the performance of the TNBCtype-4 classifier in a cohort of patients with TNBC treated with neoadjuvant …

Supplementary Figure Legends 1-5 from Identification of Aldo-Keto Reductase AKR1B10 as a Selective Target for Modification and Inhibition by Prostaglandin A1: Implications for Antitumoral Activity

Beatriz Díez-Dacal, Javier Machín Gayarre, Severine Gharbi, John F. Timms et autres

Supplementary Figure Legends 1-5 from Identification of Aldo-Keto Reductase AKR1B10 as a Selective Target for Modification and Inhibition by Prostaglandin A1: Implications for Antitumoral Activity

Supplementary Figures 1-5 from Identification of Aldo-Keto Reductase AKR1B10 as a Selective Target for Modification and Inhibition by Prostaglandin A1: Implications for Antitumoral Activity

Beatriz Díez-Dacal, Javier Machín Gayarre, Severine Gharbi, John F. Timms et autres

Supplementary Figures 1-5 from Identification of Aldo-Keto Reductase AKR1B10 as a Selective Target for Modification and Inhibition by Prostaglandin A1: Implications for Antitumoral Activity

Supplementary Figure Legends 1-5 from Identification of Aldo-Keto Reductase AKR1B10 as a Selective Target for Modification and Inhibition by Prostaglandin A1: Implications for Antitumoral Activity

Beatriz Díez-Dacal, Javier Machín Gayarre, Severine Gharbi, John F. Timms et autres

Supplementary Figure Legends 1-5 from Identification of Aldo-Keto Reductase AKR1B10 as a Selective Target for Modification and Inhibition by Prostaglandin A1: Implications for Antitumoral Activity

Supplementary Figures 1-5 from Identification of Aldo-Keto Reductase AKR1B10 as a Selective Target for Modification and Inhibition by Prostaglandin A1: Implications for Antitumoral Activity

Beatriz Díez-Dacal, Javier Machín Gayarre, Severine Gharbi, John F. Timms et autres

Supplementary Figures 1-5 from Identification of Aldo-Keto Reductase AKR1B10 as a Selective Target for Modification and Inhibition by Prostaglandin A1: Implications for Antitumoral Activity

Data from Identification of Aldo-Keto Reductase AKR1B10 as a Selective Target for Modification and Inhibition by Prostaglandin A1: Implications for Antitumoral Activity

Beatriz Díez-Dacal, Javier Machín Gayarre, Severine Gharbi, John F. Timms et autres

Abstract Cyclopentenone prostaglandins (cyPG) are reactive eicosanoids that may display anti-inflammatory and antiproliferative actions, possibly offering therapeutic potential. Here we report the identification of members of the aldo-keto reductase (AKR) family as selective targets of the cyPG prostaglandin A1 (PGA1). AKR enzymes …

Data from Identification of Aldo-Keto Reductase AKR1B10 as a Selective Target for Modification and Inhibition by Prostaglandin A1: Implications for Antitumoral Activity

Beatriz Díez-Dacal, Javier Machín Gayarre, Severine Gharbi, John F. Timms et autres

Abstract Cyclopentenone prostaglandins (cyPG) are reactive eicosanoids that may display anti-inflammatory and antiproliferative actions, possibly offering therapeutic potential. Here we report the identification of members of the aldo-keto reductase (AKR) family as selective targets of the cyPG prostaglandin A1 (PGA1). AKR enzymes …

Increased FOXJ1 protein expression is associated with improved overall survival in high-grade serous ovarian carcinoma: an Ovarian Tumor Tissue Analysis Consortium Study

Ashley L. Weir, Eunyoung Kang, Nicola S. Meagher, Gregg S Nelson et autres

BACKGROUND: Recently, we showed a >60% difference in 5-year survival for patients with tubo-ovarian high-grade serous carcinoma (HGSC) when stratified by a 101-gene mRNA expression prognostic signature. Given the varied patient outcomes, this study aimed to translate prognostic mRNA markers into protein …

au, ca, us, gb, at, de, br, pl, es (code pays fourni par la source)

CDK5RAP3, a New BRCA2 Partner That Regulates DNA Repair, Is Associated with Breast Cancer Survival

Jordi Minguillón, Marı́a José Ramı́rez, Llorenç Rovirosa, Pilar Bustamante‐Madrid et autres

BRCA2 is essential for homologous recombination DNA repair. BRCA2 mutations lead to genome instability and increased risk of breast and ovarian cancer. Similarly, mutations in BRCA2-interacting proteins are also known to modulate sensitivity to DNA damage agents and are established cancer risk …

es, us, ca (code pays fourni par la source)